Recheck blood lipids, aminotransferases (AST, ALT) and CK 4 to 8 weeks after the start of lipid-lowering drug treatment. If the target values ??can be achieved, gradually change to once every 6 to 12 months. If the blood lipids have not reached the target value when rechecked 3 to 6 months after starting treatment, the dosage or drug type should be adjusted, or combined with drug treatment, and rechecked after 4 to 8 weeks. After reaching the goal, the review period will be extended to every 6 to 12 months. During lipid-lowering drug treatment, adverse reactions must be monitored, mainly through regular testing of liver function and blood creatine kinase. If transaminase (AST/ALT) exceeds 3 times ULN (upper limit of normal), administration should be suspended. After stopping the drug, liver function still needs to be reviewed every week until it returns to normal. During medication, patients should be asked whether they have symptoms such as myalgia, muscle tenderness, muscle weakness, fatigue, and fever. If blood CK rises more than 5 times the ULN, the medication should be discontinued. If there are other acute or serious conditions that may cause myolysis during medication, such as sepsis, trauma, major surgery, hypotension and convulsions, the medication should be suspended. Lipid-lowering drugs generally need to be taken for a long time, and most patients need to take them for life. There is insufficient evidence on the safety and effectiveness of lipid-lowering drugs in children, and diet and healthy lifestyles are currently mainly advocated. However, for children with rare homozygous familial hypercholesterolemia and accompanied by obvious atherosclerosis such as skin xanthomas, safe and effective lipid-lowering drugs can also be used with caution to prevent early-onset atherosclerosis. disease. Statins are the most important and most significant drugs against atherosclerosis. They can significantly reduce the incidence and mortality of coronary heart disease and stroke (about 1/3~1/2), and significantly improve the prognosis. Therefore, Patients with coronary heart disease must make good use of statin therapy unswervingly. Even if the patient's blood lipid levels are "not high", doctors will often give the patient statins appropriately based on the condition of atherosclerosis and coronary heart disease so that the patient can benefit in the medium and long term. Most people tolerate lipid-lowering drugs very well, and the incidence of adverse reactions is very rare. If they do occur, they are mild and short-lived, and will disappear after stopping the drug. We should not lose the benefit of using lipid-lowering drugs to patients because of fear of adverse reactions. benefit. Of course, adverse reactions should be monitored regularly during medication. Lipid-lowering drugs cause a transient and mild increase in transaminase (<3 times ULN) in a few patients. This does not mean damage to liver function. There is no need to worry too much. The reason may be that it affects the intermediate link of certain transaminase metabolism. However, if transaminases are significantly elevated (>3 times ULN) and accompanied by a significant increase in bilirubin, attention should be paid to timely discontinuation of the drug and evaluation, and appropriate hepatoprotective treatment may be appropriate. Chronic liver disease and severe gout are contraindications to the use of niacin-based lipid-lowering drugs. Pregnant and lactating women should not take it. Niacin should be used with caution in patients with ulcer disease, diabetes, hepatic insufficiency, and hyperuricemia, but acipimox can be used in patients with diabetes. Those who take fenofibrate for a long time should regularly monitor liver and kidney function and creatine kinase. If there are obvious abnormalities, the dosage should be reduced or discontinued in a timely manner. It should not be used by people with poor liver and kidney function, pregnant women, lactating women, women of childbearing potential, and children. Those taking anticoagulants at the same time should pay attention to their dose adjustment. Patients with renal insufficiency should use bezafibrate with caution and the dosage should be small. Long-term users should regularly review liver and kidney function and CK activity. If there are obvious abnormalities, reduce the dosage or discontinue the drug in a timely manner. Those who take gemfibrozil for a long time should regularly review their liver and kidney functions and CK activity. If there are obvious abnormalities, they should promptly reduce the dosage or discontinue the drug.